{
    "clinical_study": {
        "@rank": "28295", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the predictive value of rapid virological response\n      (RVR) and early virological response (EVR) on sustained virological response (SVR) by stage\n      of liver fibrosis in treatment-na\u00efve patients with chronic hepatitis C genotype 1 initiated\n      on treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). Patients will be\n      followed for 48 weeks of treatment and up to 24 weeks of follow-up."
        }, 
        "brief_title": "An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Na\u00efve Patients With Chronic Hepatitis C Genotype 1", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Liver Cirrhosis", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Chronic hepatitis C genotype 1\n\n          -  Treatment-na\u00efve, i.e. have not been previously treated with pegylated interferon,\n             standard interferon and ribavirin\n\n          -  Confirmed serum positive HCV RNA\n\n          -  Liver fibrosis confirmed histologically or by fibroscan up to 24 months before\n             treatment\n\n        Exclusion Criteria:\n\n          -  Any contraindications according to the Summary of Product Characteristics for Pegasys\n             or Copegus\n\n          -  Co-infection with hepatitis B or HIV\n\n          -  Post-transplant patients\n\n          -  End stage renal disease (creatinine clearance < 15 ml/min)\n\n          -  Patients treated with immunotherapy\n\n          -  Pregnant women and male partners of women who are pregnant\n\n          -  Female patients of childbearing potential and male patients with female partners of\n             childbearing potential who are unable or unwilling to use effective and continuous\n             contraception during the treatment and for 4 months (females) and 7 months (males)\n             thereafter"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Treatment-na\u00efve patients with chronic hepatitis C genotype 1 initiated on treatment with\n        Pegasys and Copegus"
            }
        }, 
        "enrollment": {
            "#text": "196", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750216", 
            "org_study_id": "ML28344"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bydgoszcz", 
                        "country": "Poland", 
                        "zip": "85-030"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bytom", 
                        "country": "Poland", 
                        "zip": "41-902"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chorzow", 
                        "country": "Poland", 
                        "zip": "41-500"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ciechanow", 
                        "country": "Poland", 
                        "zip": "06-400"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debica", 
                        "country": "Poland", 
                        "zip": "39-200"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Katowice", 
                        "country": "Poland", 
                        "zip": "40-752"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koszalin", 
                        "country": "Poland", 
                        "zip": "75-581"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lancut", 
                        "country": "Poland", 
                        "zip": "37-100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lodz", 
                        "country": "Poland", 
                        "zip": "91-357"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mielec", 
                        "country": "Poland", 
                        "zip": "39-300"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pulawy", 
                        "country": "Poland", 
                        "zip": "24-100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Radom", 
                        "country": "Poland", 
                        "zip": "26-600"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Walbrzych", 
                        "country": "Poland", 
                        "zip": "58-300"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland", 
                        "zip": "04-141"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational Study of Peginterferon-alfa-2a (Pegasys) and Ribavirin (Copegus) on Predictive Values of RVR on Sustained Virological Response (SVR) in Different Stage of Liver Fibrosis in Treatment-na\u00efve Patients With Genotype 1 Chronic Hepatitis C", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sustained virological response (SVR) rate, in relation to rapid virological response (RVR) in different stages of liver fibrosis in treatment-na\u00efve patients with chronic hepatitis C genotype 1", 
            "safety_issue": "No", 
            "time_frame": "approximately 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750216"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Sustained virological response (SVR) rate, in relation to early virological response (EVR) in different stages of liver fibrosis in treatment na\u00efve patients with chronic hepatitis C genotype 1", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Response rates (RVR, EVR, SVR) according to host/virus/treatment-related factors in different stages of liver fibrosis (F>/=3 and </=3)", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}